GARDEN GROVE, Calif., Sept. 17, 2018 /PRNewswire/ -- C3® International, a biopharmaceutical company that has played a leadership role in the emerging cannabinoid therapeutics health sector, today officially announced the launch of its flagship Idrasil® pain management pill. Idrasil is the first standardized form of medical cannabis. It offers all of the medicinal analgesic and therapeutic benefits of cannabis, but is a superior alternative to opiates and life-threatening narcotics because physicians and caregivers can provide patients with safe, non-addictive, measurable dosages.
Conditions treated with Idrasil include, but are not limited to, AIDS; anorexia; arthritis; autism; anxiety/depression; cancer; chronic pain; glaucoma; migraines; persistent muscle spasms; Parkinson's; seizures; severe nausea; Tourette's Syndrome, and any other chronic or a persistent medical symptoms that substantially limit major life activities as defined in the Americans with Disabilities Act of 1990.
Idrasil® also offers relief for patients struggling with clinical endocannabinoid deficiencies (CECD).
CECD is a serious disorder that has a proven link to various disorders such as migraines, Fibromyalgia, Irritable Bowel Syndrome (IBS), and other treatment-resistant syndromes. Patients that want natural relief from CECD-related ailments, seek to reduce or stop existing pharmaceutical or over-the-counter dependencies, and want to curb the negative side effects or addictions of opiates and narcotics can benefit from Idrasil.
World-Class Ingredients in Purified Form
Idrasil consists of a proprietary blend of concentrated cannabis extract that is 100% natural and organic. C3's proprietary process isolates all of the cannabinoids from the cloned cannabis plant, resulting in pure natural extraction in pill form to eliminate the unwanted euphoria and social risks associated with smoking cannabis products and unpredictable dosages of edible confections. Idrasil is a natural product that looks like any pill on the market.
Additional ingredients include calcium carbonate, magnesium stearate, dicalcium phosphate, microcrystalline cellulose and silicon dioxide, which are common tabulation additives in both foods and pharmaceuticals, and are gluten free.
"Smoking and edible confections can vary greatly from plant to plant and batch to batch, which results in inconsistency and can lead to irregular analgesic or therapeutic results," said Steele Clarke Smith III, Chairman and CEO of C3 International. "With Idrasil® we have introduced quality of life in a tablet that provides the same standard and consistent results dose to dose. Cannabis has been used as medicine since earliest recorded time. Our mission is to provide safe access to Idrasil, which is a patent-pending advancement in standardized natural cannabis in a pill."
The opioid crisis shows no signs of abating in America, with various stakeholders searching for a solution to the epidemic. Idrasil is a non-addictive replacement for commonly prescribed opiates as OxyContin, Fentanyl, Morphine, Codeine as well as other common prescribed drugs such as Adderal, Humira, Phenobarbitol, Prozac, Valium, Vicodin, Xanax and Zoloft, to name a few. Cannabinoids minimize the adverse effects of opiate-based prescriptions, which can include addiction, withdrawal, depression, lack of appetite, incoherence, and constipation.
Idrasil is aseptically processed and bacteria-free with a manufacturing process that is FDA-compliant. Idrasil is manufactured in a sterile ISO 9001 certified laboratory with a standardized and consistent 12.5mg, 25mg, or 100mg dose pill. Idrasil is categorized by the FDA as Generally Regarded As Safe (GRAS).
Prescribing Idrasil and Legal Issues
Any California licensed physician can prescribe or recommend the use of medical Idrasil. Presently, Idrasil is available only to California residents according to multiple medical cannabis laws passed by the state. California passed Proposition 215 in 1996 (The Compassionate Use Act) and Senate Bill 420, was written into law in 2003, to clarify the scope of the Act for state patients, caregivers and law enforcement. Idrasil will be available in other states as the legal situation changes.
C3 offers free medical insurance billing to most major insurance providers and employer-provided policies such as PacifiCare, Aetna, Cigna, Universal Care and United Health Care, for both PPOs and HMOs and the State Compensation Insurance Fund. Prescription Idrasil is currently not covered via Kaiser, Medi-Cal or Medicare.
About Idrasil and C3 International
The mission of C3 International, Inc. is to manufacture the unique Intellectual Property for Idrasil, a major advancement in the standardization and administering of natural cannabinoids, in a tablet. Idrasil is a holistic alternative to addictive opiates and life-threatening narcotics, without euphoria. For more information on C3 International, Inc. visit www.c3internationalinc.com. To learn more about Idrasil, go to www.idrasil.com.
DISCLAIMER: THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. FURTHERMORE, NONE OF THE INFORMATION ON THIS PAGE SHOULD BE USED AS A SUBSTITUTE FOR THE ADVICE OF AN APPROPRIATELY QUALIFIED PHYSICIAN OR OTHER HEALTHCARE PROVIDER. THIS INFORMATION IS ONLY MEANT FOR INFORMATIONAL PURPOSES.
1-888-317-4687 ext. 702
SOURCE C3® International